Sandoz announces EU launch of ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer
We are facing an extraordinary paradox in modern healthcare: the better it gets, the more difficult it becomes to offer it to everyone. Currently, our healthcare systems face steadily increasing costs, driven by a steadily growing and ageing population. The extra social and economic burden of the coronavirus pandemic has further compounded the access, equity and sustainability challenges facing healthcare systems. Addressing these challenges in a balanced way will require a broad range of solutions, but one very powerful option has already been available for well over a decade: biosimilars. 15 years ago, Sandoz launched the world’s first biosimilar. Since then, biosimilars have had a substantial positive impact on patient access and healthcare systems sustainability – but we still have a way to go to unlock their full potential.
We are revisiting the commitment we have made to help make a difference for patients living with respiratory diseases
How Can We Make a Greater Impact to Improve Patients’ Lives? Pierre Bourdage via LinkedIn
Sandoz officially certified as Global Top Employer 2021
Get the latest news and updates from Sandoz and find details of our local media contacts